A phase 2 study of Thykamine in radiodermatitis associated to radiotherapy
Latest Information Update: 09 Jun 2023
At a glance
- Drugs Thykamine (Primary)
- Indications Radiodermatitis
- Focus Therapeutic Use
Most Recent Events
- 06 Jun 2023 According to a Devonian media release, the company announce that it has closed its non-brokered previously announced private placement for aggregate gross proceeds of $1,199,664.75.The proceeds of the Offering will mainly be used to finance the preparation of clinical study programs for Thykamine™ in particular the phase 2/3 program in pediatric atopic dermatitis, the phase 2 programs in radiodermatitis associated with radiotherapy.
- 19 May 2023 New trial record